MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BioSenic SA Logo
Developing ATO and cell therapies for autoimmune diseases and tissue regeneration.
Belgium
BIOS
BIOTECH Logo
Biotech group offering preclinical zebrafish testing & intein tech for human/animal health.
Spain
BST
Biovica International B Logo
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
Sweden
BIOVIC
Bonus BioGroup Ltd. Logo
Develops cell therapies and tissue products for bone grafts and inflammation repair.
Israel
BONS
BRAIN Biotech AG Logo
Develops custom enzymes and microbes for the food, nutrition, and chemical industries.
Germany
BNN
BriaCell Therapeutics Corp. Logo
Develops off-the-shelf cellular immunotherapies for advanced breast, prostate, and lung cancers.
United States of America
BCTX
BSF ENTERPRISE PLC Logo
Biotech investor developing cell-based tissue solutions for food, materials, and health markets.
United Kingdom
BSFA
BullFrog AI Holdings, Inc. Logo
Leverages causal AI to accelerate drug discovery and identify novel targets for biopharmaceuticals.
United States of America
BFRG
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America
BNR
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America
CABA

Talk to a Data Expert

Have a question? We'll get back to you promptly.